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Purpose: To evaluate the involvement of Visual System Homeobox 1 (VSX1), Secreted Protein Acidic and Rich in
Cysteine (SPARC), Superoxide Dismutase 1 (SOD1), Lysyl Oxidase (LOX), and Tissue Inhibitor of Metalloproteinase 3
(TIMP3) in sporadic and familial keratoconus.
Methods: Mutational analysis of the five genes was performed by sequencing and fragment analysis in a large cohort of
302 Italian patients, with a diagnosis of keratoconus based on clinical examination and corneal topography. The variants
identified in VSX1 and SPARC were also assessed in the available relatives of the probands.
Results: A novel mutation p.G239R and previously reported mutations were found in VSX1. Novel and already reported
variants were identified in SPARC and SOD1, whose pathogenic significance has not been established. No pathogenic
variants have been identified in LOX and TIMP3.
Conclusions: Molecular analysis of the five genes in a cohort of 225 sporadic and 77 familial keratoconus cases confirms
the possible pathogenic role of VSX1 though in a small number of patients; a possible involvement of LOX and TIMP3
could be excluded; and the role played by SOD1 and SPARC in determining the disease as not been definitively clarified.
Further studies are required to identify other important genetic factors involved in the pathogenesis and progression of
the disease that in the authors’ opinion, and according with several authors, should be considered as a complex disease.
Keratoconus (KC; OMIM 148300) is a frequent corneal
disease characterized by a progressive conical protrusion of
the cornea and no inflammatory central stroma thinning. It is
a major indication for corneal transplantation in the Western
world  [1,2],  with  a  prevalence  of  approximately  1:2,000
individuals [3,4]. The disease arises in the teenage years with
progressive  myopia  and  astigmatism  [4]  until  the  fourth
decade of life, when it usually stabilizes.
Keratoconus commonly develops as an isolated defect. It
can also be one of the findings in syndromic conditions, such
as Ehlers-Danlos, Marfan, Apert, Noonan, Down syndromes
and, less frequently, in other corneal dystrophies [5]. In the
majority of cases, the disease appears sporadic, nevertheless
familial transmission have been demonstrated in 6% to 26%
of cases [4,6-9], most commonly with an autosomal dominant
mode of inheritance with reduced penetrance. Other modes of
inheritance  have  been  described,  including  autosomal
recessive  mode  with  variable  expressivity,  multifactorial
inheritance and a major gene model [6,10].
The disease can be diagnosed by well recognized clinical
signs, including stromal thinning, Vogt’s striae, Fleischer’s
ring, and scissoring of the retinoscopic reflex with a fully-
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dilated  pupil.  The  most  sensitive  and  accurate  diagnostic
method  is  the  computer-assisted  videokeratography  that
allows for the detection of keratoconus at an early stage,
before clinical signs are evident [11,12].
In a review, Sherwin and Brookes [13] discussed the
morphological changes observed in the different structures of
keratoconic corneas (epithelium, basement membrane, nerve
fibers,  Bowman’s  layer,  stroma,  Descemet  membrane,
endothelium) and concluded that “The diversity of pathology
described  in  keratoconus  is  likely  to  represent  temporal
differences  in  the  progression  of  the  disease,  positional
differences relative to the apical centre of maximum damage
and possibly reflect a variety of pathophysiological diseases
that  make  up  the  clinical  phenotype  we  identify  as
keratoconus.” This view seem to be supported by a great
number of observations based on biochemical, genetic and
expression  studies  suggesting  a  possible  involvement  of
several genes and proteins which regulate cellular and extra
cellular processes such as proteolysis enzyme activity, wound
healing,  keratocytes  proliferation,  differentiation  and
apoptosis, increased oxidative damage (reviewed by Romero-
Jiménez [14]).
Despite the extensive research completed over the last
few decades regarding the etiology and the pathogenesis of
keratoconus, the cause(s) remain poorly understood. Up to
now, Visual System Homeobox 1 (VSX1) is the unique gene
indicated as a candidate gene in developing the disease. Its
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2482nucleotide variants have been analyzed in several populations
[15-26],  but  their  pathogenetic  role  has  still  not  been
definitively established.
Other genes, for different reasons, could be considered as
candidate genes for keratoconus.
LOX (OMIM: 153455) encodes for the protein-lysine 6-
oxidase, an extra cellular copper enzyme that initiates the
crosslinking of collagens and elastin by catalyzing oxidative
deamination of the epsilon-amino group in certain lysine and
hydroxylysine residues of collagens and lysine residues of
elastin. SPARC (OMIM: 182120), encodes for the Secreted
Protein  Acidic  and  Rich  in  Cysteine/osteonectin/BM40,  a
matrix-associated protein that elicits change in cell shape,
inhibits cell-cycle progression, and influences the synthesis of
the extracellular matrix (ECM) [27]. LOX and SPARC are
localized  on  chromosome  5q23.2  and  5q31.3-q32,
respectively, in regions that show a suggestive linkage in
familial keratoconus [9,28] and thus are both indicated as
possible candidate genes for keratoconus.
The Tissue Inhibitors of Metalloproteinases (TIMPs) are
the natural inhibitors of matrix metalloproteinases (MMPs), a
group of zinc-dependent endopeptidases that exist in both
secreted and membrane-bound forms. The balance between
MMPs and TIMPs regulates remodeling of the ECM and thus
plays a key role in a wide range of physiologic processes that
include  embryonic  development,  connective  tissue
remodeling, wound healing, glandular morphogenesis, and
angiogenesis.  Because  matrix  degrading  enzymes  could
potentially influence keratoconus progression, Matthews et al.
[29] studied the effects of TIMPs on stromal cell viability and
observed  that  the  overexpression  of  TIMP3  (OMIM:
188826) induced apoptosis in corneal stromal cell cultures. In
addition, a more recent study based on cDNA microarrays,
showed  that  TIMP3  was  differentially  expressed  in
keratoconic corneas [30].
The  Superoxide  Dismutase  Isoenzymes  (SODs)  are
differently  distributed  within  human  healthy  cornea  and
cornea of patients with KC [31]. SOD1 (OMIM: 147450) is
located on chromosome 21 while Trisomy 21 is notably at
high  risk  for  keratoconus;  thus,  a  role  in  the  increased
oxidative damage found in keratoconic corneas could not be
discarded. Udar et al. [32] screened this gene in 15 unrelated
patients and identified a 7-base genomic deletion within intron
2 in two of them. Moreover, mRNA analysis showed the
presence of two additional transcript splice variants coding for
proteins lacking the active site of the SOD1 enzyme.
In this study, we report the mutational analysis results for
VSX1, LOX, SPARC, TIMP3, and SOD1, performed in a large
cohort of Italian subjects affected by sporadic and familial
keratoconus.
METHODS
Patients:  A  total  of  302  unrelated  probands  affected  by
keratoconus from southern Italy were recruited at the Medical
Genetics  Unit  of  IRCCS  Hospital  Casa  Sollievo  della
Sofferenza (San Giovanni Rotondo, Italy).
Two hundred twenty-five (74.5%) were sporadic cases,
whereas the remaining 77 (25.5%) belonged to families in
which there were: two affected individuals in 53 pedigrees,
three individuals in 15 pedigrees, four individuals in five
pedigrees, five individuals in three pedigrees, and six in one
pedigree. Eighty-four percent of the probands had bilateral
and 16% had unilateral keratoconus. The age of onset/first
diagnosis of the disease ranged between 8 and 63 years, with
a mean (±SD) age of 25±9.5  and    28  ±9  years   observed    for
bilateral and unilateral keratoconus patients, respectively.
The diagnosis was based on slit-lamp biomicroscopy and
videokeratographic  evaluation  by  using  the  OPD-Scan
ARK-10000  (NIDEK,  Tokyo,  Japan)  and  ALLEGRO
Oculyzer  (WAVELIGHT  AG,  Erlangen,  Germany).  In
addition, individuals who had a history of the penetrating
keratoplasty  or  other  corneal  surgical  treatments  for
keratoconus  were  included  in  the  patient  cohort.  When
determining the familial segregation of the sequence variants,
all  available  family  members  underwent  a  clinical
examination  and  corneal  topography  to  examine
videokeratographic  anomalies  typical  of  clinical  or
subclinical  keratoconus,  according  to  the  criteria  of
Rabinowitz [33] and Levy et al. [8]. In addition, the thinnest
point  on  corneal  pachymetry  was  recorded.  Appropriate
informed consent was obtained from each subject, and the
study was performed according to the tenets of the Declaration
of  Helsinki.  Two-hundred  subjects  from  the  general
population were enrolled as controls. Eighty patients were
previously studied and described [16].
DNA  sequencing  analysis:  DNA  was  extracted  from
peripheral blood leukocytes by standard phenol-chloroform
methodology.  Each  DNA  fragment  was  amplified  by
polymerase chain reaction (PCR) in a final volume of 25 μl
by using 100 ng of genomic DNA. Primers used to amplify
VSX1  exons  were  those  previously  published  [16].  LOX,
SPARC,TIMP3,  and  SOD1  were  amplified  using  custom
primers,  flanking  each  exon  by  at  least  50  nucleotides,
designed using Primer 3 ([34]; Table 1). All the amplified
products  were  sequenced  in  both  forward  and  reverse
directions,  according  to  dye  terminator  chemistry  and
analyzed  on  an  ABI  3130xl  Genetic  Analyzer  (Applied
Biosystems, Foster City, CA). cDNA sequencing was used for
numbering  (GeneBank  accession  number  VSX1:
NM_014588;  SPARC:  NM_003118;  SOD1:  NM_000454;
TIMP3: NM_000362; and LOX: NM_001178102), where +1
corresponds to the A of the ATG translation initiation codon
in the reference sequence.
Fragment analysis: To test for the presence of the intronic 7-
base deletion (c.169+50delTAAACAG) in SOD1, genomic
DNA was PCR amplified using the forward primer Int2F:5′-
CAG AAA CTC TCT CCA ACT TTG C-3′, fluorescently
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Primer name Sequence TM (°C) Product size
VSX1_1F 5’-CAGCTGATTGGAGCCCTTC-3’ 58 599
VSX1_1R 5’-CTCAGAGCCTAGGGGACAGG-3’    
VSX1_2F 5’-GCACTAAAAATGCTGGCTCA-3’ 59 393
VSX1_2R 5’-GCCTCCTAGGAACTGCAGAA-3’    
VSX1_3F 5’-CATTCAGAGGTGGGGTGTT-3’ 59 419
VSX1_3R 5’-TCTTGTGGTGCCTTCAGCTA-3’    
VSX1_4F 5’-CGTTGCTTTGCTTTGGAAAT-3’ 59 394
VSX1_4R 5’-CGTTGCTTTGCTTTGGAAAT-3’    
VSX1_5F 5’-CCCCAGAGATAGGCACTGAC-3’ 59 495
VSX1_5R 5’-TGGACAATTTTTGTCTTTTGG-3’    
SPARC_2F 5’-TTGCACATATCAGGAATTCAG-3’ 58 250
SPARC_2R 5’-AGTCCCTGTTCCCTTTCAG-3’    
SPARC_3F 5’-AAGCTCCCCTAGCCTGTATC-3’ 60 250
SPARC_3R 5’-TAGCATTGAGACCCACAGC-3’    
SPARC_4F 5’-ACCTGGAACCCTTCAGCTA-3’ 58 248
SPARC_4R 5’-CTCATGTAGGCTGTCCTCGT-3’    
SPARC_5F 5’-CCCTGAGATCTGTCCAGGTA-3’ 58 294
SPARC_5R 5’-ATAGAACCACCAAGCCAACA-3’    
SPARC_6F 5’-CAGTGTCCCCATCTCTGAA-3’ 58 290
SPARC_6R 5’-GGTGGCAGAGACAGCATC-3’    
SPARC_7F 5’-ACCAATGCAGGTGGTATGT-3’ 58 348
SPARC_7R 5’-GCTCAGGGGTAAATGCAC-3’    
SPARC_8F 5’-CATGGACCTCTTGTCACACA-3’ 58 285
SPARC_8R 5’-AGGGCTTGGAGCAGTATAGG-3’    
SPARC_9F 5’-AAATATCCTTTCCTCCATGCT-3’ 58 377
SPARC_9R 5’-AGGCAGAGAGGACAGACAAC-3’    
SPARC_10F 5’-TTGCATGGCCACCTAGAC-3’ 58 246
SPARC_10R 5’-CTCCAGGCAGAACAACAAAC-3’    
SOD1_2F 5’-CAGAAACTCTCTCCAACTTTGC-3’ 59 218
SOD1_2R 5’-GAGGGGTTTTAACGTTTAGGG-3’    
LOX_1AF 5’-GAGACTGAGATACCCGTGCT-3’ 62 474
LOX_1AR 5’-AGCGGTGACTCCAGATGA-3’    
LOX_1BF 5’-TCACAGTACCAGCCTCAGC-3’ 62 500
LOX_1BR 5’-ATAGCTGGGGACCAGGTG-3’    
LOX_2F 5’-TTTTCACATTGCTTTGCAGT-3’ 56 398
LOX_2R 5’-GCTCTTGTCCCACTTCCTAA-3’    
LOX_3F 5’-TAGTTGGGAAAGGAGGATTG-3’ 58 355
LOX_3R 5’-GCAATTTTCTCCCTTCAGGT-3’    
LOX_4F 5’-GACTTATGTCCTGGGGAAAA-3’ 56 441
LOX_4R 5’-GATAAAAATGTGTGTGCTCTTCA-3’    
LOX_5F 5’-GGAGGTGCTATAAGGCTGAG-3’ 58 370
LOX_5R 5’-TTGCTTCCAATACCATGATT-3’    
LOX_6F 5’-TTCAGGGGAAAATATGCAGT-3’ 56 394
LOX_6R 5’-TGCTTACAAGAAAGCTGCTG-3’    
LOX_7AF 5’-CTTAGGTGGAGGGAAACTGT-3’ 58 485
LOX_7AR 5’-AAGTCATTTTGGCTCATTCA-3’    
LOX_7BF 5’-GCACATAACTGGATTTTGAACG-3’ 56 343
LOX_7BR 5’-TCAGCACCAGATGTGTCCAT-3’    
TIMP3_PrF 5’-AGGGGTAGCAGTTAGCATTC-3’ 60 516
TIMP3_PrR 5’-AGGAGGAGGAGAAGCCGT-3’    
TIMP3_1F 5’-ACGGCAACTTTGGAGAGG-3’ 60 273
TIMP3_1R 5’-GGGGCAGAGGAAAGGAGT-3’    
TIMP3_2F 5’-CAATTCCAGGCTCCACAGAG-3’ 60 300
TIMP3_2R 5’-CTGGCTGGTGCTTAGACACA-3’    
TIMP3_3F 5’-ACATACCCAGCAGTGGGATT-3’ 60 296
TIMP3_3R 5’-ACTGGACATTTGGTGAGTCAA-3’    
TIMP3_4F 5’-GGCTAGGCTCTGGACAAAAC-3’ 56 248
TIMP3_4R 5’-GCATTGGGAGCTGATGTTTC-3’    
TIMP3_5F 5’-GTCTGAATCCAGGCTCGGTA-3’ 56 387
TIMP3_5R 5’-TTTGCAAGAAAACAGGCACT-3’    
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Park, Milano, Italy) and the reverse primer Int2R:5′-GAG
GGG TTT TAA CGT TTA GGG-3′. The 218bp amplified
fragment was loaded on an ABI 3100 Genetic Analyzer and
analyzed  with  GeneMapper  v4.0  software  (Applied
Biosystems).  Confirmatory  sequencing  of  the  deleted
fragment was performed after re-amplification of the DNA
sample with an identical forward primer IntF2 (fluorescently
unlabeled) and Int2R.
Methylation  analysis:  One-microgram  of  genomic  DNA
purified by standard phenol-chloroform methodology from
three normal control and three keratoconic corneal tissues,
was subjected to bisulfite treatment and DNA purification
using  the  Epitect  Bisulfite  kit  (Qiagen  GmbH,  Hilden,
Germany)  according  to  the  manufacturer’s  instructions.
Bisulfite-modified DNA from the same treatment was used as
a  template  for  fluorescence-based  real-time  quantitative
Methylation-Specific PCR (QMSP). Real-time PCR using a
relative  quantification  method  with  standard  curve  to
determine  methylation  levels  was  performed  using  the
following TIMP3 primer/probe set: forward 5′-GCG TCG
GAG GTT AAG GTT GTT-3′, reverse 5′-CTC TCC AAA
ATT ACC GTA CGC G-3′; probe 5′-FAM-AAC TCG CTC
GCC  CGC  CGA  A-T  AMR  A-3′.  As  reference–gene,  a
primer/probe set specifically for the unmethylated promoter
region of the beta-actin gene (ACTB) was used: forward 5′-
TGG TGA TGG AGG AGG TTT AGT AAG T-3′; reverse 5′-
AAC CAA TAA AAC CTA CTC CTC CCT TAA-3′; probe
5′-FAM-CCA CCA CCC AAC ACA CAA TAA CAA ACA
CA-TAMRA-3′. Calibration curves for target and reference
genes were constructed using serial dilutions (90–0.009 ng)
of  a  commercially  available  fully  methylated  DNA
(CpGenome Universal Methylated DNA; Serologicals Corp.,
Norcross, GA). Amplification reactions were performed in
triplicate in a volume of 20 µl that contained 50 ng bisulfite-
modified DNA, 600 nM forward and reverse primers, 200 nM
probe, 0.6 U of Platinum Taq polymerase (Invitrogen, Inc.,
Rockville, MD), 200 µM each of dATP, dCTP, dGTP, dTTP,
and 2 µl of PCR buffer [35]. PCR conditions were as follows:
one step at 95 °C for 3 min, 50 cycles at 95 °C for 15 s, and
60 °C to 62 °C for 1 min. PCR reactions were performed in
96 well plates on an ABI PRISM 7700 Sequence detection
system (Applied Biosystems) and were analyzed by SDS 2.1.1
software  (Applied  Biosystems).  Each  plate  included
calibration  curves  for  the  ACTB  and  target  genes,  DNA
samples,  positive  controls  (CpGenomeTM  Universal
Methylated DNA; Serologicals Corp.) and negative controls
(Universal  Unmethylated  DNA;  Serologicals  Corp.),  and
multiple water blanks. The relative level of methylated DNA
was  determined  as  a  ratio  of  TIMP3  to  ACTB  and  then
multiplied by 1,000 for easier tabulation. QMSP analysis was
repeated for each sample on three separate plates and median
values were considered for statistical analyses.
DHPLC analysis: Denaturing HPLC analysis, using a nucleic
acid  fragment  analysis  system  (Wave,  3500  HT;
Transgenomic,  Crewe,  UK),  was  executed  to  exclude  the
presence of the VSX1 and SPARC nucleotide variations in
control subjects as previously described [16].
RESULTS
VSX1: The whole coding region and the exon–intron junctions
of  VSX1  were  analyzed  for  mutations  in  222  of  the  302
subjects. A novel heterozygous nucleotide change c.715G>C
leading to the substitution of the amino acid glycine with an
arginine at the codon 239 (p.Gly239Arg), was identified in the
subject K264 (Figure 1A). PolyPhen [36] and SIFT [37] tool
analysis  predicted  that  the  replaced  amino  acid  would  be
potentially  deleterious  (Table  2).  The  substitution
p.Gly239Arg  localized  in  the  CVC  domain  of  the  VSX1
protein, represents an alteration of an amino acid that has been
well  conserved  across  the  species  (Figure  1B).  DHPLC
analysis excluded the presence of this variant in 200 normal
control individuals. Molecular screening of the p.Gly239Arg
substitution  was  performed  in  all  the  family  members
available.  The  heterozygous  nucleotide  change  c.715G>C
identified in the patient was seen in the father and in other
relatives,  all  showing  some  quantitative  corneal  indices
altered (Table 3, Figure 1C).
In addition, previously reported amino acid substitutions
p.L17P, p.D144E, p.P247R, p.G160D were identified in 9
patients (Table 4). The D144E variant was also found in 1 out
of 200 controls.
The p.P247R mutation in subjects K120 and K249 was
due to the nucleotide change c.740C>G whereas in patients
K14 and K361 was due to the substitution c.740_741CG>GA
as  previously  reported  by  Heon  et  al.  [15].  Segregation
analysis  of  the  p.P247R  in  the  pedigree  of  patient  K361
showed the presence of the variation in its first son, but the
variation was absent in the remaining three child (Figure 2).
Clinical phenotype of all family members was reported in
Table 2. Two undescribed silent variants, c.348C>A (P116P)
and c.474C>G (T158T) were identified in subjects K189 and
K94, respectively.
SPARC: Mutational screening of the nine coding exons (2-10)
of  SPARC  was  performed  in  all  302  patients.  Six  novel
variants were detected, at heterozygous state, in six affected
subjects.  Three  of  them  were  silent  variations  c.204G>A
(p.A68A), c.732C>T (p.D244D), and c.747C>T (p.H249H),
while  the  remaining  were  non-synonymous  nucleotide
changes  c.187G>A  (p.E63K),  c.276G>A  (p.M92I),  c.
657C>A  (p.D219E;  Table  4).  PolyPhen  and  SIFT  tool
analysis  predicted  p.E63K  and  p.D219E  as  benign  and
tolerated variants and were discordant for p.M92I (Table 2).
The  Position  Specific  Independent  Counts  (PSIC)  score
(2.023) indicated the methionine/isoleucine substitution as
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this change as tolerated.
The analysis of conservation across species showed that
the aspartic acid at position 219 is the more well conserved
amino  acid  residue;  in  Xenopus  laevis  the  methionine  at
position 92 is replaced by a leucine that has biochemical
proprieties very similar to the isoleucine; while the glutamic
acid at position 63 is the least conserved amino acid residue
Figure 1. Analysis of the c.715G>C (p.G239R) sequence variant in VSX1 exon 4. A: DNA sequence electropherogram of the c.715G>C
(p.G239R) sequence variant in VSX1 exon 4 (NM_014588). B: multiple sequence alignment of the amino acid sequences of VSX1 in different
species. Alignments were performed using the program Clustal (provided in the public domain by European Bioinformatics Institute, European
Molecular Biology Laboratory, Heidelberg, Germany). C: segregation of p.G239R in family K264. Each individual was reported by age (in
years), genotype and videokeratographs. Filled symbols refer to keratoconus individual, whereas open symbols are individuals without clinical
keratoconus.
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analysis, in the 200 control individuals. The p.E63K variant
was inherited by patient K15 from his healthy mother, but the
variant was absent in his keratoconic father who underwent
penetrating keratoplasty. Additionally, the c.747C>T variant
did not segregate with keratoconus in the pedigree of K66
patient (data not shown). No relatives of the other patients
were  available  to  study  the  possible  segregation  of  the
identified variants with the keratoconus. In addition, seven
known single nucleotide polymorphisms (SNPs) rs7714314,
rs2304052, rs2116780, rs2304051, rs1978707, rs41290587,
and rs1053411 have been detected. The frequencies observed
were  compatible  with  the  HapMap  [39]  information  for
Europeans.
SOD1: Exon 2 and the flanking intronic regions of SOD1 were
PCR  amplified  using  a  fluorescent  labeled  primer.  The
fragments analysis allowed the identification of the 7-base
deletion c.169+50delTAAACAG in two patients, K151 and
K283, both affected by apparently sporadic keratoconus. This
intronic deletion was absent in 200 controls. Figure 4 reports
the electropherograms of the fragments and the sequencing
analysis.
TIMP3:  No  TIMP3  mutations  or  novel  variants  were
identified by sequencing of the 5 coding exons and the 516-
bp fragment including part of the 5′ UTR, as well as CpG
islands, putative binding sites for SP1, and a possible TATA
box  [34].  Two  known  SNPs  were  detected,  rs9862  and
rs11547635,  showing  alleles  frequency  compatible  with
HapMap data. Quantitative Methylation-Specific PCR was
performed  to  determine  methylation  status  of  the  TIMP3
promoter region in three normal and three keratoconic corneal
tissues. Methylation was not detected in any of the samples
analyzed (data not shown).
LOX: Sequencing of the whole coding sequence of LOX did
not reveal novel variants. Two annotated SNPs were detected.
The A allele of SNP rs41407546 (c.476C>A, p.P159Q) was
found in heterozygosis in five individuals. Eight subjects were
found homozygous and 78 were heterozygous for the A allele
of SNP rs1800449 (c.473G>A, R158Q); the frequency of G
allele (0.844) and A allele (0.155) were compatible with the
HapMap [38] information for Europeans.
DISCUSSION
Keratoconus  is  a  heterogeneous  condition  with  variable
clinical expression. Several hypotheses have been proposed
concerning the genetic, environmental, biomechanical, and
biochemical causes. In spite of a huge amount of research
conducted  to  elucidate  the  etiology  and  the  disease
progression, VSX1 is the sole gene indicated as an important
genetic  factor  in  determining  the  keratoconus.  However,
although the pathogenic role of VSX1 is now accepted by
many authors, only a small number of patients show mutations
in this gene. Moreover, several loci for the disease have been
mapped [9,28,39-47] and a large number of genes have been
shown up- or down-regulated in keratoconic corneal tissues
[30,48-58].  These  observations  confirm  the  genetic
heterogeneity of the disease and also support the hypothesis
that in some pedigrees the defect could be inherited as a
multifactorial trait.
In this study, we evaluated a possible role played by five
genes  in  determining  keratoconus  in  a  large  cohort  of
individuals affected by sporadic or familial disease. The novel
VSX1change c.715G>C (p.G239R) was found in one affected
patient and in several unaffected relatives all showing corneal
abnormalities at the videokeratography measurements.
The presence of this variant in unaffected relatives might
suggest that it is a rare polymorphism without any pathogenic
role. However the absence in 200 controls along with the
PolyPhen  and  SIFT  prediction  and  the  high  conservation
across the species suggests it could be a pathogenic change.
On the other hand we can not exclude that this variant could
be a causative mutation with incomplete penetrance or low
expressivity yielding corneal abnormalities in the unaffected
relatives but causing significant damage in association with
other  genes  or  the  environment  in  the  affected  patient.In
addition, other previously reported amino acid substitutions
p.L17P, p.D144E, p.P247R, p.G160D were identified in nine
subjects (one familial and eight sporadic cases). These results
demonstrate the incidence of VSX1 mutant alleles in 5.9% (18
out of 302) among the cohort of Italian patients.
TABLE 2. IN SILICO ANALYSIS OF NOVEL VSX1 AND SPARC VARIANTS.
Gene Protein
alteration
Polyphen analysis
(PSIC score)
SIFT analysis
(Score)
Prediction
VSX1 p.G239R 2.172 <0.05 Probably damaging/deleterious
SPARC p.E63K 0.63 0.13 Benign/tolerated
SPARC p.M92I 2.023 0.45 Probably damaging/tolerated
SPARC p.D219E 0.827 0.16 Benign/tolerated
        The prediction of functional impact of missense changes identified was performed using two homology based programs                                                                                                                                   
        PolyPhen (Polymorphism Phenotyping) [37] and SIFT (Sorting Intolerant From Tolerant) [38] analysis tool. PSIC:
(Position Specific Independent Counts).
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2487A large debate exists in the research community whether
the  VSX1  variations  identified  in  keratoconus  have  to  be
regarded  as  disease-related  mutations  or  simply
nonpathogenic variants.
Looking  at  the  results  obtained  in  previous  studies
[15-26],  as  well  as  in  the  present  study,  it  is  possible  to
summarize the main findings as follows:
a. Six of the VSX1 potential mutations, p.L17P,
p.N151S,  p.G160V,  p.R166W,  p.Q175H,  and
p.G239R were identified exclusively in keratoconus
patients  and  in  their  relatives  showing  corneal
abnormalities, but these mutations were absent in the
controls.
b. The p.G160D and p.P247R amino acid changes
were found in keratoconus patients but they were
also associated with mildly abnormal functions of
the  inner  retina  on  electroretinography  (ERG)
examination  and  with  Posterior  Polymorphous
Corneal  Dystrophy  [15].  In  addition,  since  the
p.G160D variation was absent in two out of four
relatives with suspected keratoconus in an Italian
family  studied  [16],  its  pathogenic  role  was  not
definitively clarified. None of the two variants has
been identified in the controls.
c. The p.H244R, p.L159M, and p.D144E variants
were also found in three unaffected relatives and in
seven  out  of  1312  (0.53%)  controls  analyzed.  In
addition, p.D144E did not show inheritance in two
families [18,23]. For these reasons, all three VSX1
variants  may  be  considered  as  polymorphisms
without pathogenic significance.
d. Totally, VSX1 sequence variations were found
in 42 out of 1,350 (3.1%) keratoconus probands and
in seven out of 1,412 (0.49%) controls.
TABLE 3. QUANTITATIVE AND QUALITATIVE VIDEOKERATOGRAPHIC PARAMETERS EVALUATED ON KERATOCONUS PATIENTS AND THEIR RELATIVES.
Subject ID Age
(years)
Eye K AST Abs (I-S) Srax KISA Pachymetry Corneal
shape *
Family K264
II:1 55 OD 44.10 0.9 0.36 1 4.8 525 H
    OS 43.50 0.7 0.42 32 136.4 522 J
II:2 60 OD 43.60 0.8 0.5 20 116.3 539 Jinv
    OS 44.50 2.8 0.48 23 458.5 550 J
II:3 56 OD 44.20 0.4 0.6 1 3.5 503 B
    OS 44.30 0.4 0.26 1 1.5 505 B
II:5 48 OD 43.00 1.6 0.3 15 103.2 524 I
    OS 43.10 2 0.7 15 301.7 517 I
III:1 42 OD 40.2 1.3 - - - 517 -
    OS 40.1 1.3 - - - 495 -
III:2 39 OD 44.00 1.1 1.32 30 638.9 508 J
    OS 48.30 4.1 9 60 33645 445 D
III:3 13 OD 46.40 1.1 0.32 20 108.9 566 J
    OS 45.50 0.7 0.98 1 10.4 556 F
Family K361
I:1 45 OD 43.72 1.62 2.89 60 4093 558 D
    OS 43.94 1.38 1.67 55 1856 548 D
I:2 43 OD 43.50 2.07 2.95 75 6641 491 D
    OS 43.10 1.31 3.02 60 3410 489 D
II:1 16 OD 42.82 0.77 0.89 27 264 505 J
    OS 43.72 0.89 0.69 23 206 504 J
II:2 14 OD 45.85 0.75 0.48 18 99 543 G
    OS 45.43 1.95 0.32 2.5 24 535 J
II:3 11 OD 43.10 0.76 0.28 7 21 672 F
    OS 43.05 0.71 0.04 5 2 674 F
II:4 9 OD 45.36 0.98 0.84 11 137 529 J
    OS 45.46 1.28 0.16 13 40 527 J
         OD=right eye; OS=left eye; K=central keratometry; AST=regular corneal astigmatism; Abs (I-S)=absolute value of inferior-
         superior dioptric asymmetry; Srax=skewed radial axis index; KISA=K x Abs(I-S) x AST x Srax/3; Pachymetry refers to the
         thinnest point on the cornea; *corneal shapes classification as reported by Levi et al. [9].
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2488In summary, even if there is controversial evidence for
some  variations,  (i.e.,  p.D144E,  p.L159M,  p.G160D,  and
p.H244R), the role of VSX1 in the pathogenesis of keratoconus
cannot be absolutely excluded, as stated by some authors
[19].  In  fact,  those  variations  also  identified  in  healthy
relatives of the patients and in the general population cannot
be automatically considered simply as neutral polymorphism
for several reasons. First, the “normal controls,” or unaffected
relatives,  carrying  mutations  apparently  could  be
asymptomatic and may present subtle corneal abnormalities
at the very end of the keratoconus phenotypical spectrum that
could  be  revealed  by  pachymetric  and  posterior  corneal
surface maps, in addition to the videokeratography analysis
[20]. Second, some variations among controls may represent
incompletely penetrant mutations that could be pathogenic in
another patient. Third, the segregation analysis performed by
several authors supports either the autosomal dominant model
of inheritance or the recessive one. Nevertheless, it cannot be
excluded as the hypothesis of a major gene model and a
multifactorial disease. In these latter cases, the VSX1 changes
found in keratoconus patients and in their normal relatives
could represent genetic predisposition factors (a defect in one
TABLE 4. MUTATIONAL ANALYSIS OF VSX1, SPARC, AND SOD1 IN 302 SUBJECTS AFFECTED BY KERATOCONUS.
Gene Patient ID Nucleotide change Protein
alteration
Controls
VSX1 K33*, K74*, K75*, K124, K295# c.50T>C p.L17P 0/200
  K5*, K66*, K96, K161, K305 c.432C>G p.D144E 1/200
  K35*, K74*, K179 c.479G>A p.G160D 0/200
  K264 c.715G>C p.G239R§ 0/200
  K14*#, K120, K249, K361 c.740_741CG>GA c.740C>G p.P247R 0/200
SPARC K15# c.187G>A p.E63K 0/200
  K34 c.276G>A p.M92I 0/200
  K43 c.657C>A p.D219E 0/200
  K66 c.747C>T p.H249H 0/200
  K166 c.732C>T p.D244D 0/200
  K188 c.204G>A p.A68A 0/200
SOD1 K151 c.169+50delTAAACAG - 0/200
  K283 c.169+50delTAAACAG - 0/200
*Patients previous described [16]; # familial case; 
§ novel mutation.
Figure 2. Segregation analysis of the VSX1 mutation p.P247R in family K361. Each individual was reported by age (in years), genotype and
videokeratographs. Filled symbols refer to keratoconus individuals, whereas open symbols are individuals without clinical keratoconus.
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2489of the multiple factors needed to manifest the pathological
phenotype).
SPARC is found widely in extracellular matrices and is
predominantly expressed during embryogenesis and in adult
tissues undergoing remodeling or repair. It is believed to play
a  modulator  role  in  cell-cell  and  cell-matrix  interactions,
differentiation,  ECM  production  and  organization,  wound
healing, and angiogenesis [59-61]. In the eye, an increased
SPARC level has been correlated with cataract [62], corneal
wound repair [63], proliferative diabetic retinopathy [64], and
glaucoma [65]. A possible role of SPARC in keratoconus has
been hypothesized because of its function [27] and position
[9]. Sequencing analysis of the gene allowed us to identify
three novel variants leading to the amino acids substitutions
p.E63K, p.M92I, and p.D219E. Data obtained by in silico
analysis prediction and segregation analysis in the available
pedigrees, though they are not sufficient to definitively rule
out  the  involvement  of  SPARC  in  keratoconus,  seem  to
suggest that the variations found have to be considered rare
polymorphisms rather than causative mutations and further
investigations are required.
SOD1 is a major cytoplasmic antioxidant enzyme that
metabolizes  superoxide  radicals  to  molecular  oxygen  and
hydrogen peroxide, thus providing a defense against oxygen
toxicity  [66].  SOD1  mutations  are  associated  with
amyotrophic lateral sclerosis (ALS) [67,68]. A possible role
in keratoconus was postulated because of its function and its
chromosomal  position.  The  presence  of  the  c.
169+50delTAAACAG change, the unique SOD1 variant that
was found associated to the keratoconus, was evaluated in the
patients in this study. Udar et al. [32] identified this intronic
deletion in two patients and demonstrated its segregation with
keratoconus  in  only  one  of  the  two  pedigrees  studied.  A
subsequent study performed on 113 patients failed to identify
the deletion [24]. In this study, the c.169+50delTAAACAG
deletion  was  identified  in  two  out  of  302  patients.  Both
subjects appeared to be sporadic cases, and no relatives were
included in the study. Taking into account the total number of
unrelated patients studied, this SOD1 variation was found in
four out of 430 (0.9%), whereas it was absent in a total of 456
controls analyzed. Thus, a possible causative role of SOD1 in
the pathogenesis of keratoconus needs to be further studied.
LOX and TIMP3 play a pivotal role in extracellular matrix
maturation and remodeling, respectively, two process that
could influence the loss of corneal structural components,
leading to corneal thinning typical of keratoconus. Defects in
TIMP3 are the cause of Sorsby fundus dystrophy (OMIM
136900), a rare autosomal dominant macular disorder with
age of onset in the fourth decade. Moreover, overexpression
of TIMP3 induces apoptosis in corneal stromal cell cultures
[29]. Molecular analysis of both genes revealed no causative
mutations in the cohort of patients but only known SNPs.
Moreover, QMSP analysis performed in three keratoconic
corneal tissues excluded methylation in the TIMP3 promoter
Figure  3.  A:  DNA  sequence
chromatogram of the SPARC variations:
c.187G>A  (p.E63K),  c.276G>A
(p.M92I),  and  c.657C>A  (p.D219E;
NM_003118).  B:  multiple  sequence
alignment of the amino acid sequences
of  SPARC  in  different  species.
Alignments were performed using the
program Clustal.
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2490region. The results seem to exclude a possible role of these
two genes in keratoconus.
In conclusion, in the present study, a mutational screening
in  a  large  cohort  of  unrelated  keratoconus  patients  was
performed and the results were analyzed. The results confirm
the possible pathogenic role of VSX1 though in a small number
of patients, allow to exclude a possible involvement of LOX
and TIMP3 (at least in the study’s population), while not
definitively clarifying the possible role played by SOD1 and
SPARC in determining the disease.
Further studies are required to identify other important
genetic factors involved in the pathogenesis and progression
of the disease which, in the authors’ opinion (and according
to several other authors), should be considered a complex
disease. As for many other complex traits, it is the time to shift
the research approach to large consortiums combined with
genome-wide association studies, with whole exome or entire
genome sequencing. Such efforts will hopefully shed new
light on the molecular genetics of the keratoconus.
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